



🤎 @evnia_dk



IFUs and all available labelling material (including Operative Techniques if applicable)

- Sales data for the last five years (at least)
- PMS and PMCF plans and reports; latest PSUR (if available and applicable)

Important Note: explain to the Manufacturer the requirement to provide complaint data by date and country/region

- CAPAS (if any)
- Up to date Risk files including Residual Risk Reports

Important Note: explain to the Manufacturer the requirement to cross-check the identified residual risks with the literature and external vigilance data

 Non-clinical data; Verification/Validation data including biocompatibility data and data on packaging, usability and shelf-life

- Device-specific Clinical data (e.g. manufacturer-initiated clinical investigations)

Go through the provided files together!

✤ Identify any gaps and/or missing information and escalate them to the Manufacturer. It will be much more time-consuming to wait for pending information during the writing process

✤ Ask the Manufacturer to approve your search terms BEFORE executing any literature and vigilance searches

Discuss the intended clinical benefits and identify safety and performance claims along with the Manufacturer.

Frame the performance and safety endpoints you will be discussing in the clinical evaluation and confirm them before starting the writing process

Clarify the intentions of the Manufacturer with respect to potential requirements for additional PMCF activities

🥑 @evnia_dk